FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
News|Articles|September 24, 2026
The Healthcare Insight Gap: Why Generic AI Falls Short and What Healthcare Marketers Need Instead
Author(s)LiveWorld
How Human-Led, AI-Powered systems designed specifically for healthcare turn data overload into decision-ready insight. Healthcare marketers are flooded with data, from patient conversations and HCP feedback to social listening, CRM activity, and market signals, yet actionable insights remain difficult to uncover. This eBook explores why generic AI often falls short in healthcare and shows how a Human-Led, AI-Powered approach can turn complex data into trusted, decision-ready intelligence.
Related to this article
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Trending on PharmExec
1
FDA Launches Rare Disease Framework Initiative
2
The Role That 503B Outsourcing and Compounding Pharmacies Actually Play in Filling Supply Gaps
3
Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5